why choose us

First received: September 19, 2022

Clinical Trial: A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer

Study Status: ACTIVE_NOT_RECRUITING

Recruit Status: ACTIVE_NOT_RECRUITING

Condition: Castration-Resistant Prostatic Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 2, Randomized, Open-label, Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants With Metastatic Castration-resistant Prostate Cancer

Brief Summary: Study CP-MGC018-03 is a randomized, open-label, Phase 2 study.The study will enroll participants with metastatic castration-resistant prostate cancer (mCRPC) previously treated with one prior androgen receptor axis-targeted therapy (ARAT).ARAT includes abiraterone, enzalutamide, or apalutamide.Participants may have received up to 1 prior taxane-containing regimen, but no other chemotherapy agents.The study will assess efficacy and tolerability of two vobramitamab duocarmazine (MGC018) experimental arms (2.0…

Read more